MedTrace Logo

Complete Remission After Treatment With Biologics for Nasal Polyps

NCT07268313 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-12-05

No results posted yet for this study

Summary

In this RCT the investigators randomize patients who are treated with biologic treatment (Nucala or Dupixent) due to nasal polyps and have controlled disease within the last year to either stop treatment og continue as a control group.

Conditions

  • Nasal Polyps

Interventions

DRUG

DUPIXENT®

Continue Dupixent

DRUG

NUCALA®

"Continue Nucala

OTHER

Dupi discontinuation

Stop taking Dupixent at baseline; no substitute is given

OTHER

Mepo discontinuation

Stop taking Nucala at baseline; no substitute is given

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-03
Primary Completion
2027-06-01
Completion
2027-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07268313 on ClinicalTrials.gov